Diabetes Care
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Diabetes Care 29:722-724, 2006
DOI: 10.2337/diacare.29.03.06.dc05-2148
© 2006 by the American Diabetes Association
This Article
Right arrow Extract Freely available
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Cigolini, M.
Right arrow Articles by Targher, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cigolini, M.
Right arrow Articles by Targher, G.
Social Bookmarking
Add to CiteULike   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Cardiovascular and Metabolic Risk
Brief Report

Serum 25-Hydroxyvitamin D3 Concentrations and Prevalence of Cardiovascular Disease Among Type 2 Diabetic Patients

Massimo Cigolini, MD1, Maria Pina Iagulli, MD1, Valentino Miconi, MD1, Micaela Galiotto, MD1, Simonetta Lombardi, MD1 and Giovanni Targher, MD2

1 Department of Medicine, Observatory of Clinical Epidemiology sen. Giacometti, Hospital of Arzignano, Arzignano, Vicenza, Italy
2 Diabetes Unit, Sacro Cuore Hospital, Negrar, Italy

Address correspondence reprint requests to Giovanni Targher, MD, Diabetes Unit, Ospedale Sacro Cuore–don G. Calabria, Via Sempreboni, 5, 37024 Negrar (VR), Italy. E-mail: targher{at}sacrocuore.it

Abbreviations: 25(OH)D, 25-hydroxyvitamin D3 • CRP, C-reactive protein • CVD, cardiovascular disease


   INTRODUCTION
TOP
 INTRODUCTION
RESEARCH DESIGN AND METHODS
 RESULTS
 CONCLUSIONS
 References
 
Accumulating research suggests that low 25-hydroxyvitamin D3 [25(OH)D] concentrations may be inversely associated with type 2 diabetes (1,2,3), metabolic syndrome (4,5), insulin resistance (6), and cardiovascular disease (CVD) (7).

Much remains to be learned, however, about the relationships between vitamin D status, metabolic syndrome, and CVD. Furthermore, the published data in humans arguing that hypovitaminosis D is a CVD risk factor remain conflicting (8,9).

Because this topic has received scant attention and the available information on associations between vitamin D status and CVD among type 2 diabetic adults was lacking, we examined the relationships between serum 25(OH)D concentrations and prevalent CVD in type 2 diabetic adults.


   RESEARCH DESIGN AND METHODS
TOP
 INTRODUCTION
 RESEARCH DESIGN AND METHODS
RESULTS
 CONCLUSIONS
 References
 
We studied 459 consecutive type 2 diabetic outpatients attending our clinic after exclusion of those with recent acute illness or advanced chronic liver or renal disease and those who were taking medications known to alter vitamin D metabolism. The control group consisted of 459 (64% men, age 61 ± 6 years) age- and sex-matched nondiabetic volunteers.

Biochemical blood measurements were determined by standard laboratory procedures. Serum 25(OH)D concentrations were measured during winter months using an automated chemiluminescence immunoassay (DiaSorin Liaison). Metabolic syndrome was defined according to the Adult Treatment Panel III criteria (10). Presence of coronary (myocardial infarction, angina, or revascularization procedures), cerebrovascular (ischemic stroke, recurrent transient ischemic attacks, or carotid endarterectomy), and peripheral (claudication, lower-extremity amputation, or revascularization procedures) vascular disease was confirmed by chart review, medical history and examination, and vascular laboratory studies.

Data are means ± SD or frequencies. Skewed variables were logarithmically transformed to improve normality before analysis. Statistical analyses included unpaired t test, {chi}2 test, and logistic regression analysis. In this latter analysis, CVD was considered as an aggregate end point inclusive of patients with at least one atherosclerotic manifestation. In fully adjusted logistic regression models, sex, age, BMI, smoking, diabetes duration, HbA1c (A1C), LDL cholesterol, calcium, creatinine, albumin excretion rate, use of medications, metabolic syndrome, and inflammatory markers (fibrinogen or C-reactive protein [CRP]) were also included as covariates. Hypovitaminosis D was defined as a serum 25(OH)D concentration <20 ng/ml (6,11,12).


   RESULTS
TOP
 INTRODUCTION
 RESEARCH DESIGN AND METHODS
 RESULTS
CONCLUSIONS
 References
 
The mean (±SD) 25 (OH) D concentration was 24.1 ± 9.1 ng/ml (median 22.3, range 4.9–91.0) among control subjects and 19.7 ± 10 ng/ml (17, 3–76) among diabetic patients. The age- and sex-adjusted prevalence of hypovitaminosis D was higher in diabetic patients than in control subjects (60.8 vs. 42.8%, P < 0.001).

As shown in Table 1, diabetic patients with hypovitaminosis D were more likely to be women and had increased prevalence of higher values of A1C, triglycerides, CRP, and fibrinogen than their vitamin D–sufficient counterparts. The proportion using insulin, lipid-lowering, or antiplatelet drugs was higher among those with hypovitaminosis D, whereas the proportion using hypoglycemic drugs was similar in both groups. Age, BMI, waist circumference, diabetes duration, smoking, LDL cholesterol, creatinine, calcium, albuminuria, and metabolic syndrome components did not differ between the groups.


View this table:
[in this window]
[in a new window]
  		Table 1— Baseline characteristics of the study participants, grouped according to vitamin D status

 
Overall, 143 (31.1%) of 459 patients were coded positive for CVD. Of these, 81 patients had coronary heart disease, 51 had cerebrovascular disease, and 41 had peripheral vascular disease; many subjects had CVD in multiple sites. As shown in Table 1, the prevalence of CVD was greater among those with hypovitaminosis D. Similarly, 25(OH)D was lower (P < 0.01) among those with CVD (17.9 ± 9 vs. 20.6 ± 10 ng/ml), coronary disease (17 ± 9 vs. 20.3 ± 10 ng/ml), and cerebrovascular disease (16.9 ± 7 vs. 20 ± 10 ng/ml) than among those without CVD.

In logistic regression analysis, the association between hypovitaminosis D and prevalent CVD (odds ratio 1.70 [95% CI 1.1–2.6], P < 0.01) remained statistically significant after adjustment for classical risk factors, A1C, metabolic syndrome, renal function tests, calcium, and use of medications (1.77 [1.1–2.9], P = 0.023); additional adjustment for fibrinogen (or CRP) levels abolished this association (1.43 [0.9–2.3], P = NS). Almost identical results were obtained in models that included the individual components of metabolic syndrome and in models in which a more restrictive threshold to define hypovitaminosis D (≤15 ng/ml) was used (13).


   CONCLUSIONS
TOP
 INTRODUCTION
 RESEARCH DESIGN AND METHODS
 RESULTS
 CONCLUSIONS
References
 
We found a high prevalence of hypovitaminosis D and a strong inverse association between 25(OH)D concentrations and prevalent CVD among type 2 diabetic outpatients. Interestingly, our data suggest that the putative elevated CVD risk associated with hypovitaminosis D is probably mediated by correlated elevations in plasma inflammatory markers. Moreover, since elevations of CRP and fibrinogen levels increase the risk for CVD (14), these findings could help to explain the CVD excess typically observed during winter months, a period in which vitamin D status tends to be poor (15), and suggest a rationale for vitamin D supplementation in prevention of CVD, especially in the elderly.

Our findings are supported by few available data in humans showing that 25(OH)D levels are inversely related to coronary artery calcifications (16,17) and are lower in patients with myocardial infarction (7) and by experimental studies (18–22) suggesting that low 25(OH)D influences the activity/expression of macrophages and lymphocytes in atherosclerotic plaques, thus promoting chronic inflammation in the artery wall. Interestingly, in two recent clinical trials (23,24), vitamin D supplementation markedly reduced serum levels of CRP, interleukin-6, and tissue matrix metalloproteinases. Additionally, low vitamin D3 concentrations result in elevations of parathyroid hormone, which has been linked to insulin resistance and significant increases in the serum levels of many acute-phase proteins (25).

Evidently, these findings are all consistent with the proposition that hypovitaminosis D and subsequent secondary hyperparathyroidism may promote the acute phase response and may help to explain how hypovitaminosis D might act as a risk factor for CVD.

This study has some limitations. Because our study was a cross-sectional one, the causative nature of the associations cannot be established. Additionally, parathyroid hormone and 1{alpha},25(OH)D were not measured in this study. Further investigation is necessary to evaluate whether hypovitaminosis D is associated with incident CVD among type 2 diabetic adults and to determine possible mechanisms of any preventive effect from vitamin D supplementation against CVD.


   Footnotes
 
A table elsewhere in this issue shows conventional and Système International (SI) units and conversion factors for many substances.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received for publication November 4, 2005. Accepted for publication November 21, 2005.


   References
TOP
 INTRODUCTION
 RESEARCH DESIGN AND METHODS
 RESULTS
 CONCLUSIONS
 References
 

  1. Boucher BJ, Mannan N, Noonan K, Hales CN, Evans SJ: Glucose intolerance and impairment of insulin secretion in relation to vitamin D deficiency in East London Asians. Diabetologia 38:1239–1245, 1995[Medline]
  2. Isaia G, Giorgino R, Adami S: High prevalence of hypovitaminosis D in female type 2 diabetic population (Letter). Diabetes Care 24:1496, 2001[Free Full Text]
  3. Scragg R, Sowers M, Bell C: Serum 25-hydroxyvitamin D, diabetes, and ethnicity in the Third National Health and Nutrition Examination Survey. Diabetes Care 27:2813–2818, 2004[Abstract/Free Full Text]
  4. Boucher BJ: Inadequate vitamin D status: does it contribute to the disorders comprising syndrome X? Br J Nutr 79:315–327, 1998[Medline]
  5. Ford ES, Ajani UA, McGuire LC, Liu S: Concentrations of serum vitamin D and the metabolic syndrome among U.S. adults. Diabetes Care 28:1228–1230, 2005[Free Full Text]
  6. Chiu KC, Chu A, Go VL, Saad MF: Hypovitaminosis D is associated with insulin resistance and beta cell dysfunction. Am J Clin Nutr 79:820–825, 2004[Abstract/Free Full Text]
  7. Scragg R, Jackson R, Holdaway I, Lim T, Beaglehole R: Myocardial infarction is inversely associated with plasma 25-hydroxyvitamin D3 levels: a community-based study. Int J Epidemiol 19: 559–563, 1990
  8. Holick MF: Vitamin D: importance in the prevention of cancers, type 1 diabetes, heart disease, and osteoporosis. Am J Clin Nutr 79:362–371, 2004[Abstract/Free Full Text]
  9. Norman PE, Powell JT: Vitamin D, shedding light on the development of disease in peripheral arteries. Arterioscler Thromb Vasc Biol 25:39–46, 2005[Abstract/Free Full Text]
  10. National Cholesterol Education Program: Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 285:2486–2497, 2001[Free Full Text]
  11. Fuleihan GE, Deeb M: Hypovitaminosis D in a sunny country. N Engl J Med 340:1840–1841, 1999[Free Full Text]
  12. Looker AC, Dawson-Hughes B, Calvo MS, Gunter EW, Sahyoun NR: Serum 25-hydroxyvitamin D status of adolescents and adults in two seasonal subpopulations from NHANES III. Bone 30:771–777, 2002[Medline]
  13. Thomas MK, Lloyd-Jones DM, Thadhani RI, Shaw AC, Deraska DJ, Kitch BT, Vamvakas EC, Dick IM, Prince RL, Finkelstein JS: Hypovitaminosis D in medical inpatients. N Engl J Med 338:777–783, 1998[Abstract/Free Full Text]
  14. Willerson JT, Ridker PM: Inflammation as a cardiovascular risk factor. Circulation 109(Suppl. 1):2–10, 2004
  15. Pell JP, Cobbe SM: Seasonal variations in coronary heart disease. QJM 92:689–696, 1999[Abstract/Free Full Text]
  16. Doherty T, Tang W, Dascolas S, Watson KE, Demer LL, Shavelle R, Detrano R: Ethnic origin and serum levels of 1,25-dihydroxyvitamin D3 are independent predictors of coronary calcium mass measured by electron-beam computed tomography. Circulation 96:1477–1481, 1997[Abstract/Free Full Text]
  17. Watson KE, Abrolat ML, Malone LL, Hoeg JM, Doherty T, Detrano R, Demer LL: Active serum vitamin D levels are inversely correlated with coronary calcification. Circulation 96:1755–1760, 1997[Abstract/Free Full Text]
  18. Brown A, Dusso A, Slatopolsky E: Vitamin D. Am J Physiol 277:F157–F175, 1999[Medline]
  19. Barsony J, Prufer K: Vitamin D receptors and retinoid X receptors interactions in motion. Vitam Horm 65:345–376, 2002[Medline]
  20. Pierce R, Kolodzie M, Parks W: 1,25-dihydroxyvitamin D3 repress tropoelastin expression by a posttranscriptional mechanism. J Biol Chem 267:11593–11599, 1992[Abstract/Free Full Text]
  21. Veldman C, Cantorna M, DeLuca H: Expression of 1,25 dihydroxyvitamin D3 receptor in the immune system. Arch Biochem Biophys 374:334–338, 2000[Medline]
  22. Willheim M, Thien R, Schrattbauer K, Bajna E, Holub M, Gruber R, Baier K, Pietschmann P, Reinisch W, Scheiner O, Peterlik M: Regulatory effects of 1alpha, 25 dihydroxyvitamin D3 on the cytokine production of human peripheral blood lymphocytes. J Clin Endocrinol Metab 84:3739–3744, 1999[Abstract/Free Full Text]
  23. Van den Berghe G, Van Roosbroeck D, Vanhove P, Wouters PJ, De Pourcq L, Bouillon R: Bone turnover in prolonged critical illness: effect of vitamin D. J Clin Endocrinol Metab 88:4623–4632, 2003[Abstract/Free Full Text]
  24. Timms PM, Mannan N, Hitman GA, Noonan K, Mills PG, Syndercombe-Court D, Aganna E, Price CP, Boucher BJ: Circulating MMP9, vitamin D and variation in the TIMP-1 response with VDR genotype: mechanisms for inflammatory damage in chronic disorders? QJM 95:787–796, 2002[Abstract/Free Full Text]
  25. McCarty MF: Secondary hyperparathyroidism promotes the acute phase response:a rationale for supplemental vitamin D in prevention of vascular events in the elderly. Med Hypotheses 64:1022–1026, 2005[Medline]

Add to CiteULike CiteULike   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 Rheumatology (Oxford)Home page
J. E. Do, S. Y. Kwon, S. Park, and E.-S. Lee
Effects of vitamin D on expression of Toll-like receptors of monocytes from patients with Behcet's disease
Rheumatology, June 1, 2008; 47(6): 840 - 848.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
T. J. Wang, M. J. Pencina, S. L. Booth, P. F. Jacques, E. Ingelsson, K. Lanier, E. J. Benjamin, R. B. D'Agostino, M. Wolf, and R. S. Vasan
Vitamin D Deficiency and Risk of Cardiovascular Disease
Circulation, January 29, 2008; 117(4): 503 - 511.
[Abstract] [Full Text] [PDF]

Home page
 Nephrol Dial TransplantHome page
M. Chonchol, M. Cigolini, and G. Targher
Association between 25-hydroxyvitamin D deficiency and cardiovascular disease in type 2 diabetic patients with mild kidney dysfunction
Nephrol. Dial. Transplant., January 1, 2008; 23(1): 269 - 274.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
A. G. Pittas, J. Lau, F. B. Hu, and B. Dawson-Hughes
The Role of Vitamin D and Calcium in Type 2 Diabetes. A Systematic Review and Meta-Analysis
J. Clin. Endocrinol. Metab., June 1, 2007; 92(6): 2017 - 2029.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
A. G. Pittas, S. S. Harris, P. C. Stark, and B. Dawson-Hughes
The Effects of Calcium and Vitamin D Supplementation on Blood Glucose and Markers of Inflammation in Nondiabetic Adults
Diabetes Care, April 1, 2007; 30(4): 980 - 986.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Extract Freely available
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Cigolini, M.
Right arrow Articles by Targher, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cigolini, M.
Right arrow Articles by Targher, G.
Social Bookmarking
Add to CiteULike   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Diabetes Diabetes Care Clinical Diabetes Diabetes Spectrum